Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

Overview of attention for article published in Journal of Hematology & Oncology, September 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 1 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,928 followers.

New article: Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine https://t.co/H6lYofkqkS #colorectalcancer #oncology https://t.co/ULI75HKfBE

30 Sep 2021

Reply Repost Favourite

RT @NK_papers: Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel…

30 Sep 2021

Reply Repost Favourite

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine by Zhaojin Yu https://t.co/5kfaEEmM5b

30 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.